The cancer biomarkers market focuses on biological molecules—such as proteins, genes, or other measurable indicators—used to detect, diagnose, monitor, and predict the progression or treatment response of various cancers. These biomarkers are critical in early cancer detection, personalized medicine, and drug development. Key types include genetic markers, protein biomarkers, and epigenetic indicators, applied through technologies like PCR, next-generation sequencing (NGS), immunoassays, and imaging. Market growth is driven by the rising global incidence of cancer, increasing demand for targeted therapies, and ongoing advances in genomics and proteomics. Pharmaceutical and biotechnology companies use biomarkers extensively in clinical trials to identify patient populations and monitor treatment efficacy. North America leads the market due to strong research infrastructure, high healthcare spending, and numerous biomarker-based diagnostic approvals, while Asia-Pacific is poised for rapid expansion as cancer prevalence rises and healthcare investments grow. Challenges include the high cost of biomarker tests, complex regulatory requirements, and the need for standardized validation across diverse patient populations.
The global cancer biomarkers market size was valued at USD 38.14 billion in 2024. The market is projected to grow from USD 42.87 billion in 2025 to USD 74.62 billion by 2032, exhibiting a CAGR of 8.2% during the forecast period. North America dominated the cancer biomarkers market with a 35.99% share in 2024, supported by advanced diagnostic infrastructure, strong research funding, and the rising adoption of personalized medicine in oncology care.
The report covers the cancer biomarkers market in depth, including segmentation by cancer type (breast, lung, colorectal, prostate, others), biomarker type (PSA, HER-2, EGFR, KRAS, others), end user (pharmaceutical & biotechnology companies; diagnostics & research labs; hospitals & specialty clinics; others), and geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). Historical data spans 2019-2023, with base year 2024, estimate year 2025, and forecast period 2025-2032.
The report divides the market by cancer type into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. Among these, the breast cancer segment dominated in 2024, thanks to its high incidence and growing emphasis on early detection and awareness.
The lung cancer segment is expected to grow at a significant CAGR during 2025‐2032, driven by increasing R&D investment in lung cancer biomarkers.
The categories include PSA, HER-2, EGFR, KRAS, and others. In 2024, the HER-2 biomarker held the largest revenue share, mainly due to breast cancer prevalence and the introduction of novel tests, particularly liquid biopsy‐based diagnostics.
The EGFR biomarker segment is projected to grow fastest, aligned with rising lung cancer cases and increasing demand for diagnostic testing.
The market is segmented into pharmaceutical & biotechnology companies; diagnostics & research laboratories; hospitals & specialty clinics; and others. Diagnostics & research laboratories held the dominant share in recent years, due to the growing introduction of new diagnostic products.
Also, pharmaceutical & biotechnology companies are increasingly using these biomarkers for drug discovery and development; hospitals and specialty clinics are another growing channel due to increasing in‐patient testing.
North America not only held the largest share (~35.99%) in 2024, but it also continues to lead in innovation, technology adoption, and clinical trial activity.